Omega-3 supplement for pulmonary hypertension
Part of Lungs & breathing clinical trials.
This study tests a new omega-3 supplement to see if it can reduce inflammation and improve blood vessel function in people with pulmonary arterial hypertension (PAH). You might be eligible if your PAH is stable and you haven't been taking other fish oil products.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 75 years old
- Diagnosed with certain types of pulmonary arterial hypertension (idiopathic, hereditary, drug-induced, or related to connective tissue disease)
- On stable PAH treatment for at least 3 months
- Able to understand the study and give consent
- Not currently taking fish oil supplements or omega-3 medications like Omacor
- No serious heart, kidney, or other medical conditions that could interfere
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IMC-003 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can help improve symptoms and exercise ability when added to your current PAH medications.
This trial tests whether an oral supplement made from special fats (called Specialized Pro-resolving Mediators) can help reduce blood vessel damage caused by inflammation in people with obesity and high blood pressure. If you have well-controlled high blood pressure and are obese, you may be able to join.
This trial tests a combination of three medications (an endothelin receptor antagonist, a PDE5 inhibitor, and sotatercept) as the first treatment for people newly diagnosed with pulmonary arterial hypertension (PAH). It aims to see if starting with all three together works better than the usual approach.
This study tests whether two types of omega-3s (EPA and DHA) help improve HDL (good cholesterol) and reduce blood clot risk in people with high triglycerides and low HDL cholesterol.
This study follows people with different types of high blood pressure in the lungs (pulmonary hypertension) to see how starting specific lung blood vessel medicines affects outcomes. It may help improve how clinicians choose and monitor treatment over time.
This study tests a supplement containing omega-3 fats to see how it affects levels of DHA and EPA in your blood. If you're a healthy adult, you might join to help learn if this supplement can boost these important fats.
Hear when a new PAH trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.